Connections Christian Counseling, Llc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 12600 N 113th Ave, C-19, Youngtown, AZ 85363 Phone: 623-584-7800 |
Innerquest Llc Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 12600 N 113th Ave Ste C19, Youngtown, AZ 85363 Phone: 480-650-6241 |
Engaging Life Center Psychologist - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 12600 N 113th Ave Ste B9, Youngtown, AZ 85363 Phone: 602-845-0767 Fax: 602-715-0647 |
News Archive
Cleveland-Diascopic LLC, a Cleveland-based medical research company that develops diagnostic technology, will use a highly competitive federal grant to develop and apply new artificial intelligence and digital pathology tools for detecting tuberculosis.
The University of Cambridge and Life Technologies Corporation, announced today the formation of a collaboration to advance translational research studies in key disease areas such as cancer, diabetes and neurological disorders. Through this collaboration, next generation sequencing technology will be made available to the European research and clinical communities through the Eastern Sequence and Informatics Hub at Addenbrooke's Hospital in Cambridge.
Cephalon, Inc. today announced that the company received a second Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the supplemental new drug application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV] for the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. In its letter to the company, the FDA reiterated its previously stated concerns regarding the NUVIGIL sNDA.
For patients with Clostridium difficile (C. difficile), a persistent and potentially deadly bacterial illness, severe diarrhea, abdominal pain, nausea and vomiting are an everyday event. This particularly virulent infection is prone to recurrence, even after multiple courses of expensive antibiotics, and treatment options are limited for patients who continually relapse or develop antibiotic resistance.
Sanofi and Pluromed Inc. announced today that they have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts.
› Verified 4 days ago